Cullinan Therapeutics (CGEM) CSO sells 4,000 shares in Rule 10b5-1 trade

Rhea-AI Filing Summary

Cullinan Therapeutics, Inc. insider trading report: Chief Scientific Officer Jennifer Michaelson reported a sale of company stock. On January 22, 2026, she sold 4,000 shares of Cullinan Therapeutics common stock at a price of $12.30 per share in an open-market transaction. The sale was carried out under a pre-established Rule 10b5-1 trading plan that was put in place on August 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, Michaelson directly beneficially owned 128,635 shares of Cullinan Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Michaelson Jennifer

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		4,000	D	$12.3	128,635	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) disclose in this Form 4?

The filing shows that Chief Scientific Officer Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics common stock at $12.30 per share on January 22, 2026.

How many Cullinan Therapeutics (CGEM) shares does the CSO own after this transaction?

After the reported sale, Chief Scientific Officer Jennifer Michaelson beneficially owned 128,635 shares of Cullinan Therapeutics common stock directly.

Was the Cullinan Therapeutics (CGEM) insider sale part of a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected pursuant to a plan established under Rule 10b5-1 on August 7, 2025, indicating it followed a pre-arranged trading plan.

Who is the insider involved in this Cullinan Therapeutics (CGEM) Form 4?

The reporting person is Jennifer Michaelson, who serves as Chief Scientific Officer of Cullinan Therapeutics, Inc.

What type of security was involved in the Cullinan Therapeutics (CGEM) insider sale?

The transaction involved common stock of Cullinan Therapeutics, Inc., reported as a non-derivative security in Table I of the Form 4.

Was this Cullinan Therapeutics (CGEM) Form 4 transaction direct or indirect ownership?

The Form 4 identifies the ownership of the reported shares as direct (D), with no nature of indirect beneficial ownership indicated.